Please wait while the formulary information is being retrieved.
TEMODAR (TEMOZOLOMIDE)
- Anaplastic astrocytoma
- Glioblastoma multiforme
- Temozolomide Capsule
- Temodar Iv Solution
- Temodar Intravenous Solution
- Temodar Capsule
- Temodar Cap
- By Indication
100 mg capsule
- 150 mg/m2 by oral route once daily on an empty stomach, preferably at bedtime, for 5 days sequentially per 28 day cycle
140 mg capsule
- 150 mg/m2 by oral route once daily on an empty stomach, preferably at bedtime, for 5 days sequentially per 28 day cycle
180 mg capsule
- 150 mg/m2 by oral route once daily on an empty stomach, preferably at bedtime, for 5 days sequentially per 28 day cycle
20 mg capsule
- 150 mg/m2 by oral route once daily on an empty stomach, preferably at bedtime, for 5 days sequentially per 28 day cycle
250 mg capsule
- 150 mg/m2 by oral route once daily on an empty stomach, preferably at bedtime, for 5 days sequentially per 28 day cycle
5 mg capsule
- 150 mg/m2 by oral route once daily on an empty stomach, preferably at bedtime, for 5 days sequentially per 28 day cycle
100 mg intravenous solution
- Dosage information is not available
100 mg intravenous solution
- Dosage information is not available
100 mg capsule
- 150 mg/m2 by oral route once daily on an empty stomach, preferably at bedtime, for 5 days sequentially per 28 day cycle
140 mg capsule
- 150 mg/m2 by oral route once daily on an empty stomach, preferably at bedtime, for 5 days sequentially per 28 day cycle
180 mg capsule
- 150 mg/m2 by oral route once daily on an empty stomach, preferably at bedtime, for 5 days sequentially per 28 day cycle
20 mg capsule
- 150 mg/m2 by oral route once daily on an empty stomach, preferably at bedtime, for 5 days sequentially per 28 day cycle
250 mg capsule
- 150 mg/m2 by oral route once daily on an empty stomach, preferably at bedtime, for 5 days sequentially per 28 day cycle
5 mg capsule
- 150 mg/m2 by oral route once daily on an empty stomach, preferably at bedtime, for 5 days sequentially per 28 day cycle
100 mg capsule
- 150 mg/m2 by oral route once daily on an empty stomach, preferably at bedtime, for 5 days sequentially per 28 day cycle
140 mg capsule
- 150 mg/m2 by oral route once daily on an empty stomach, preferably at bedtime, for 5 days sequentially per 28 day cycle
180 mg capsule
- 150 mg/m2 by oral route once daily on an empty stomach, preferably at bedtime, for 5 days sequentially per 28 day cycle
20 mg capsule
- 150 mg/m2 by oral route once daily on an empty stomach, preferably at bedtime, for 5 days sequentially per 28 day cycle
250 mg capsule
- 150 mg/m2 by oral route once daily on an empty stomach, preferably at bedtime, for 5 days sequentially per 28 day cycle
5 mg capsule
- 150 mg/m2 by oral route once daily on an empty stomach, preferably at bedtime, for 5 days sequentially per 28 day cycle
Anaplastic astrocytoma
- 150 mg/m2 by oral route once daily on an empty stomach, preferably at bedtime, for 5 days sequentially per 28 day cycle
- 200 mg/m2 by oral route once daily on an empty stomach, preferably at bedtime, for 5 days sequentially per 28 day cycle
- Infuse 200 mg/m2 over 90 minute(s) by intravenous route once daily for 5 days sequentially per 28 day cycle
- Infuse 75 mg/m2 over 90 minute(s) by intravenous route once daily for42 days
- Infuse 75 mg/m2 over 90 minute(s) by intravenous route once daily for49 days
- Infuse 150 mg/m2 over 90 minute(s) by intravenous route once daily for 5 days sequentially per 28 day cycle
Glioblastoma multiforme
- 150 mg/m2 by oral route once daily on an empty stomach, preferably at bedtime, for 5 days sequentially per 28 day cycle
- 200 mg/m2 by oral route once daily on an empty stomach, preferably at bedtime, for 5 days sequentially per 28 day cycle
- Infuse 200 mg/m2 over 90 minute(s) by intravenous route once daily for 5 days sequentially per 28 day cycle
- Infuse 75 mg/m2 over 90 minute(s) by intravenous route once daily for42 days
- Infuse 75 mg/m2 over 90 minute(s) by intravenous route once daily for49 days
- Infuse 150 mg/m2 over 90 minute(s) by intravenous route once daily for 5 days sequentially per 28 day cycle
- adenovirus vac live type-4 & 7
- adenovirus vaccine live type-4
- adenovirus vaccine live type-7
- BCG vaccine, live (PF)
- flu vac,qval 2013-14 (2-49yrs)
- Flumist 2013-2014
- M-m-r Ii (pf)
- measles,mumps&rubella vacc(PF)
- measles,mumps,rub,varicel(PF)
- natalizumab
- Proquad (pf)
- Rotateq Vaccine
- rotavirus vaccine live, penta
- typhoid vaccine
- Tysabri
- varicella virus vacc live (PF)
- Varivax (pf)
- Vivotif Berna Vaccine
- yellow fever vaccine live (PF)
- Yf-vax (pf)
- Zostavax (pf)
- zoster vaccine live (PF)
Contraindicated
- clozapine
- Clozaril
- deferiprone
- Fazaclo
- Ferriprox
- Versacloz
Severe
Moderate
- None
- Lactating mother
Contraindicated
- Abnormal hepatic function tests
- Anemia
- Aplastic anemia
- Bone marrow depression
- Myelodysplastic syndrome
- Neutropenic disorder
- Pancytopenia
- Pneumocystis jirovecii pneumonia
- Pregnancy
- Thrombocytopenic disorder
Severe
Moderate
- Lymphopenia
TEMODAR (TEMOZOLOMIDE)
- Anaplastic astrocytoma
- Glioblastoma multiforme
- Diabetes insipidus
- Memory impairment
- Seizure disorder
- Thrombocytopenic disorder
- Alopecia
- Anorexia
- Ataxia
- Blurred vision
- Constipation
- Dizziness
- Fatigue
- General weakness
- Headache disorder
- Nausea
- Paresthesia
- Skin rash
- Viral infection
- Vomiting
More Frequent
Severe
Less Severe
- Anemia
- Dyspnea
- Hemorrhage
- Herpes simplex infection
- Herpes zoster
- Infection
- Leukopenia
- Lymphopenia
- Neutropenic disorder
- Stomatitis
- Agitation
- Aphasia
- Arthralgias
- Back pain
- Diarrhea
- Diplopia
- Drowsy
- Dry skin
- Dysgeusia
- Dyspepsia
- Erythema
- Fever
- Flu-like symptoms
- Gait abnormality
- Hallucinations
- Hearing loss
- Hyperglycemia
- Indifference
- Insomnia
- Mood changes
- Musculoskeletal pain
- Oral candidiasis
- Parosmia
- Peripheral edema
- Petechiae
- Pharyngitis
- Pruritus of skin
- Sinusitis
- Symptoms of anxiety
- Tooth disorder
- Urinary tract infection
- Urinary urgency
- Weight gain
- Weight loss
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Alveolitis
- Anaphylaxis
- Aplastic anemia
- Cholestasis
- Cytomegalovirus disease
- Erythema multiforme
- Hemiplegia
- Hepatic failure
- Hepatitis
- Herpes simplex encephalitis
- Hyperbilirubinemia
- Hypertension
- Interstitial pneumonitis
- Intracerebral hemorrhage
- Malignant neoplasm of bone marrow
- Myelodysplastic syndrome
- Opportunistic fungal infection
- Opportunistic viral infection
- Pancytopenia
- Pneumocystis jirovecii pneumonia
- Protozoal infection
- Pulmonary fibrosis
- Reactivation of hepatitis B
- Stevens-johnson syndrome
- Toxic epidermal necrolysis
Less Severe
- Abdominal pain with cramps
- Acute confusion
- Cough
- Depression
- Dyskinesia
- Dysphasia
- Mastalgia
- Myalgias
- Urinary incontinence
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Temozolomide
No efficacy established in pediatric studies of brain stem glioma and astrocytoma.
- 1 Day – 18 Years
- No efficacy established in pediatric studies of brain stem glioma and astrocytoma.
Temozolomide
- Severity Level:
D
- Additional Notes: Fetal malformations and embryolethality seen in rats/rabbits at less than mrhd.
Contraindicated
Temozolomide
Potential serious adv effects on infant; contraindicated per briggs
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Potential serious adv effects on infant; contraindicated per briggs |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Temozolomide
General-Patients older than 70 years of age are at increased risk for myelosuppression.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | N | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Anaplastic astrocytoma | |
| C71 | Malignant neoplasm of brain |
| C71.0 | Malignant neoplasm of cerebrum, except lobes and ventricles |
| C71.1 | Malignant neoplasm of frontal lobe |
| C71.2 | Malignant neoplasm of temporal lobe |
| C71.3 | Malignant neoplasm of parietal lobe |
| C71.4 | Malignant neoplasm of occipital lobe |
| C71.5 | Malignant neoplasm of cerebral ventricle |
| C71.6 | Malignant neoplasm of cerebellum |
| C71.7 | Malignant neoplasm of brain stem |
| C71.8 | Malignant neoplasm of overlapping sites of brain |
| C71.9 | Malignant neoplasm of brain, unspecified |
| Glioblastoma multiforme | |
| C71 | Malignant neoplasm of brain |
| C71.0 | Malignant neoplasm of cerebrum, except lobes and ventricles |
| C71.1 | Malignant neoplasm of frontal lobe |
| C71.2 | Malignant neoplasm of temporal lobe |
| C71.3 | Malignant neoplasm of parietal lobe |
| C71.4 | Malignant neoplasm of occipital lobe |
| C71.5 | Malignant neoplasm of cerebral ventricle |
| C71.6 | Malignant neoplasm of cerebellum |
| C71.7 | Malignant neoplasm of brain stem |
| C71.8 | Malignant neoplasm of overlapping sites of brain |
| C71.9 | Malignant neoplasm of brain, unspecified |
| 0-9 | A-Z |
|---|---|
| C71 | Malignant neoplasm of brain |
| C71 | Malignant neoplasm of brain |
| C71.0 | Malignant neoplasm of cerebrum, except lobes and ventricles |
| C71.0 | Malignant neoplasm of cerebrum, except lobes and ventricles |
| C71.1 | Malignant neoplasm of frontal lobe |
| C71.1 | Malignant neoplasm of frontal lobe |
| C71.2 | Malignant neoplasm of temporal lobe |
| C71.2 | Malignant neoplasm of temporal lobe |
| C71.3 | Malignant neoplasm of parietal lobe |
| C71.3 | Malignant neoplasm of parietal lobe |
| C71.4 | Malignant neoplasm of occipital lobe |
| C71.4 | Malignant neoplasm of occipital lobe |
| C71.5 | Malignant neoplasm of cerebral ventricle |
| C71.5 | Malignant neoplasm of cerebral ventricle |
| C71.6 | Malignant neoplasm of cerebellum |
| C71.6 | Malignant neoplasm of cerebellum |
| C71.7 | Malignant neoplasm of brain stem |
| C71.7 | Malignant neoplasm of brain stem |
| C71.8 | Malignant neoplasm of overlapping sites of brain |
| C71.8 | Malignant neoplasm of overlapping sites of brain |
| C71.9 | Malignant neoplasm of brain, unspecified |
| C71.9 | Malignant neoplasm of brain, unspecified |
Formulary Reference Tool